Home
About
About CPD Network
Mission & Vision
Purpose
Governance
Compliance
Physician Organization Checklist
Microsites
Members
Experts
CMEX Databse
Contact
Login
Home
About
About CPD Network
Mission & Vision
Purpose
Governance
Compliance
Physician Organization Checklist
Microsites
Members
Experts
CMEX Databse
Contact
Login
FR
EN
Program Resources
Guideline Recommendations
Recent CV/RENAL Outcome Trials with Antihyperglycemic Agents in Type 2 Diabetes
Supporting Slides
Program Key Learnings
Reference List
Updates (Recent Additions)
Other Resources and Tools
Diabetes Canada Pharmacologic Management: 2020 Update
Diabetes Canada Pharmacologic Management: 2020 Update – User’s Guide
The 2018 Clinical Practice Guidelines - Quick Reference Guide
Antihyperglycemic Agents and Renal Function
KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD
Sick-Day Medication List
Pharmacotherapy for Type 2 Diabetes Interactive Tool
Reducing Vascular Risk Interactive Tool
Self-Monitoring Blood Glucose (SMBG) Interactive Tool
Articles
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes (DECLARE)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced)
Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD)
Program Materials
Program Slides
Program Slides for Virtual Sessions
Facilitator Guide
Patient Worksheet Handout
Speaker Training Video
Check your downloads!
cpdisup
